Arcturus Therapeutics (NASDAQ:ARCT) Trading 13.7% Higher – What’s Next?

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)’s share price was up 13.7% on Thursday . The stock traded as high as $17.78 and last traded at $17.7340. 423,802 shares traded hands during mid-day trading, a decline of 30% from the average session volume of 604,122 shares. The stock had previously closed at $15.60.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arcturus Therapeutics in a research note on Friday, July 17th. Wall Street Zen upgraded shares of Arcturus Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Sunday, August 9th. Finally, Roth Capital reissued a “buy” rating and issued a $41.00 price target on shares of Arcturus Therapeutics in a report on Wednesday, September 2nd. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Arcturus Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $23.00.

Arcturus Therapeutics Stock Up 11.8%

The stock has a market cap of $495.84 million, a price-to-earnings ratio of -5.28 and a beta of 2.48. The company’s 50-day simple moving average is $10.06 and its 200-day simple moving average is $8.49.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings data on Friday, August 7th. The biotechnology company reported ($0.84) EPS for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.16. The company had revenue of $2.96 million during the quarter, compared to the consensus estimate of $3.11 million. Arcturus Therapeutics had a negative return on equity of 46.54% and a negative net margin of 317.62%. As a group, analysts expect that Arcturus Therapeutics Holdings Inc. will post -3.48 EPS for the current fiscal year.

Hedge Funds Weigh In On Arcturus Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. Two Sigma Securities LLC purchased a new position in shares of Arcturus Therapeutics during the second quarter valued at $80,000. Diversify Advisory Services LLC acquired a new position in shares of Arcturus Therapeutics in the 2nd quarter valued at about $91,000. ADAR1 Capital Management LLC acquired a new position in shares of Arcturus Therapeutics in the 1st quarter valued at about $116,000. Corient Private Wealth LP purchased a new stake in shares of Arcturus Therapeutics in the second quarter worth approximately $117,000. Finally, Castleview Partners LLC purchased a new stake in shares of Arcturus Therapeutics in the first quarter worth approximately $130,000. Hedge funds and other institutional investors own 94.54% of the company’s stock.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc is a biotechnology company focused on developing medicines based on messenger RNA (mRNA) and other RNA technologies. The company’s platform includes LUNAR, a lipid-mediated delivery system designed to transport nucleic acid medicines into targeted cells, and STARR, a self-amplifying mRNA technology intended to produce therapeutic proteins from relatively small doses of RNA.

Arcturus is developing RNA-based candidates for rare diseases, infectious diseases, and other conditions.